In one paragraphArticle in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Karl Laviolette *Infinity, Toulouse Institute for Infectious and Inflammatory Diseases, University of Toulouse, Inserm U1291, CNRS U5051, Toulouse, France.
Ambrine SahalCentre de Recherche en Cancérologie de Toulouse, Université de Toulouse, Inserm U1037, CNRS U5071, Toulouse, France.
Claire DétravesInfinity, Toulouse Institute for Infectious and Inflammatory Diseases, University of Toulouse, Inserm U1291, CNRS U5051, Toulouse, France.
Romain TorresInfinity, Toulouse Institute for Infectious and Inflammatory Diseases, University of Toulouse, Inserm U1291, CNRS U5051, Toulouse, France.
Clothilde DemontInfinity, Toulouse Institute for Infectious and Inflammatory Diseases, University of Toulouse, Inserm U1291, CNRS U5051, Toulouse, France.
Véronique AdoueInfinity, Toulouse Institute for Infectious and Inflammatory Diseases, University of Toulouse, Inserm U1291, CNRS U5051, Toulouse, France.
Olivier P JoffreInfinity, Toulouse Institute for Infectious and Inflammatory Diseases, University of Toulouse, Inserm U1291, CNRS U5051, Toulouse, France. olivier.joffre@inserm.fr.ORCID http://orcid.org/0000-0003-1168-8165 Funding
Agence Nationale de la Recherche (French National Research Agency) ANR-20-CE15-0005Fondation ARC pour la Recherche sur le Cancer (ARC Foundation for Cancer Research) ARCPJA2021060003837Fondation pour la Recherche Médicale (Foundation for Medical Research in France) AJE201212Fondation pour la Recherche Médicale (Foundation for Medical Research in France) EQU202203014703
6 · The paper itselfAbstract
Protective immune responses require close interactions between conventional (Tconv) and regulatory T cells (Treg). The extracellular mediators and signaling events that regulate the crosstalk between these CD4
Indexed as
CD4-Positive T-LymphocytesChromosomal Proteins, Non-HistoneGene SilencingGraft RejectionHeterochromatinT-Lymphocytes, RegulatoryAllograftsAnimalsAntigens, CDBone Marrow TransplantationChromobox Protein Homolog 5Lymphocyte Activation Gene 3 ProteinMethyltransferasesMiceMice, Inbred C57BLMice, KnockoutAntigens, CDChromobox Protein Homolog 5Chromosomal Proteins, Non-HistoneHeterochromatinLag3 protein, mouseLymphocyte Activation Gene 3 ProteinMethyltransferasesPdcd1 protein, mouseProgrammed Cell Death 1 ReceptorRepressor ProteinsSuv39h1 protein, mouse
Identifiers
PMID39794349
PMCPMC11723947
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390